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Abstract
Background: Since the Influenza A pandemic in 1819, the association between the influenza virus and
Streptococcus pneumoniae has been well described in literature. While a leading role has been so far attributed
solely to Influenza A as the primary infective pathogen, Influenza B is generally considered to be less pathogenic
with little impact on morbidity and mortality of otherwise healthy adults. This report documents the severe
synergistic pathogenesis of Influenza B infection and bacterial pneumonia in previously healthy persons not
belonging to a special risk population and outlines therapeutic options in this clinical setting.
Case Presentation: During the seasonal influenza epidemic 2007/2008, three previously healthy women presented
to our hospital with influenza-like symptoms and rapid clinical deterioration. Subsequent septic shock due to
severe bilateral pneumonia necessitated intensive resuscitative measures including the use of an interventional
lung assist device. Microbiological analysis identified severe dual infections of Influenza B with Streptococcus
pyogenes in two cases and Streptococcus pneumoniae in one case. The patients presented with no evidence of
underlying disease or other known risk factors for dual infection such as age (< one year, > 65 years), pregnancy or
comorbidity.
Conclusions: Influenza B infection can pose a risk for severe secondary infection in previously healthy persons. As
patients admitted to hospital due to severe pneumonia are rarely tested for Influenza B, the incidence of admission
due to this virus might be greatly underestimated, therefore, a more aggressive search for influenza virus and
empirical treatment might be warranted. While the use of an interventional lung assist device offers a potential
treatment strategy for refractory respiratory acidosis in addition to protective lung ventilation, the combined
empiric use of a neuraminidase-inhibitor and antibiotics in septic patients with pulmonary manifestations during an
epidemic season should be considered.
Background
As early as 1903, French physician R. T. H. Laennec noted
that the prevalence of pneumonia increased following an
influenza epidemic [1]. This association between the influ-
enza virus and Streptococcus pneumoniae became most
obvious during the Influenza A pandemic of 1918, during
which an estimated 40 to 50 million, mostly young and
otherwise healthy people died, probably due to secondary
bacterial pneumonia. Several reviews in the years after the
pandemic led to the conclusion that bacteria were second-
ary pathogens and not the primary affecting agents [2].
There is evidence that the majority of deaths in the 1919
and subsequent 1957 and 1968 pandemics resulted
directly from secondary bacterial pneumonia caused by
common upper respiratory tract bacteria. These findings
indicate, that addressing the viral cause alone by antiviral
therapy and vaccination might not be sufficient, leading to
a serious debate on pre-emptive empirical antibiotic ther-
apy to cover the possibility of life-threatening secondary
bacterial infections [3,4]. In regards of pandemic influenza
planning, the importance of treating bacterial complica-
tions might be significantly higher in developing countries
as neuraminidase inhibitors and vaccines might not be
available to the majority of people [5].* Correspondence: aebit@uhbs.ch
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So far a leading role has been attributed solely to
Influenza A as the primary infective pathogen, while
Influenza B is generally considered to be less patho-
genic, having little impact on morbidity and mortality of
otherwise healthy adults. We report for the first time
severe secondary bacterial pneumonia with septic shock
following infection with Influenza B in previously
healthy women presenting to our hospital during the
influenza season 2007/2008.
Case Presentation
Patient 1
A 39-year-old, previously healthy woman presented to
the emergency unit with a 3-day history of myalgia,
chills, high fever and a sore throat as well as vomitus,
diarrhea and headaches. She was febrile, tachypnoeic
with a respiratory rate of 40 per minute and showed an
oxygen saturation of 92% despite receiving 10 litres of
oxygen via face mask. She was tachycardic and hypoten-
sive, indicating a septic shock. A patchy exanthema was
visible on her trunk, and rales were noted upon bilateral
auscultation. Her laboratory findings revealed a leucope-
nia of 2.9 ×10-9/l, a CRP of 507 mg/l and a procalcito-
nin of 139 ng/ml (Table 1). A chest x-ray showed
diffuse infiltrates bilaterally.
Blood cultures and expectorate were taken, and anti-
biotic therapy was initiated with intravenous ceftriaxone
2 g/day. Due to further respiratory deterioration, the
patient was intubated. Aggressive volume replacement
and high dose vasopressors were needed to stabilize the
hypotensive shock. Haemofiltration was started for acute
renal failure. After a diagnostic bronchoscopy with
bronchoalveolar lavage on the day of admission, the
antibiotic therapy was empirically changed to piperacil-
lin/tazobactam 4.5 g 3 times daily and clarythromycin
500 mg twice daily. Oseltamivir 75 mg twice daily was
added for 5 days, as the history was suspicious for influ-
enza disease with bacterial superinfection. Due to pro-
gressive, refractory hypercapnia and respiratory acidosis,
an interventional lung assist device (iLA membrane ven-
tilator, Nova Lung®, Talheim, Germany) was installed
the same day.3
Group A streptococci grew in four (of four drawn)
blood cultures as well as in the bronchoalveolar lavage
fluid. Taking the clinical picture into account, a strepto-
coccal toxic shock syndrome was diagnosed, and the
antibiotic therapy was changed to high-dose penicillin
(5 Mio U four times a day). Clindamycin 900 mg three
times daily was added to prevent toxin production for
3 days. A 5 day immunoglobulin therapy (Redimmune®
0.4 g/kg/d) was started. The bronchoalveolar lavage was
repeated 5 days after admission to look for viral patho-
gens and confirmed the presence of Influenza B by
real-time polymerase chain reaction (RT-PCR4) with
40,565 copies/ml (Table 1).
Over the following days, a nosocomial, ventilator-
associated pneumonia was diagnosed and the antibiotic
therapy was empirically changed to imipenem 500 mg
four times a day. Methicillin susceptible Staphylococcus
aureus was detected by culture of respiratory samples.
Following clinical improvement, the lung assist device
was removed after 11 days and the antibiotic therapy
was stopped after 14 days. A third episode of respiratory
deterioration occurred 2 weeks after admission. No
pathogen could be isolated from bronchoalveolar lavage.
The recurrence of severe respiratory acidosis due to
refractory hypercarbia required another lung assist
device, and a dilatational tracheotomy was performed.
After 24 days of intensive care, the patient’s condition
had finally improved enough for the lung assist device
to be removed; the patient was weaned successfully and
decanulated on day 35. The patient was transferred to a
rehabilitation facility with mild critical illness polyneuro-
pathy. She showed no neurological deficits otherwise.
Patient 2
A previously healthy 27-year-old woman presented with
complaints of an influenza-like infection with sore
throat, fever and dry coughs since three days. The night
before admission her sore throat became worse, fever
climbed to 39°C and she complained of headaches. On
admission, she was clinically diagnosed as having influ-
enza, received intravenous fluids, and her discharge was
planned thereafter. Within 8 hours post admission, her
general condition deteriorated rapidly, showing progres-
sive hypotension and respiratory failure. She was alert
but in a bad general condition, fulfilling all criteria of a
septic shock. Her laboratory findings on admission
showed a leukocyte count of 12 ×10-9/l, a CRP of 103
mg/l and a procalcitonin level of 34 ng/ml (Table 1). A
chest x-ray showed infiltrations in the right lung consis-
tent with pneumonia. After blood cultures were drawn,
an antibiotic therapy with amoxicillin/clavulanic acid 2.2
g three times daily and clarithromycin 500 mg twice
daily was initiated and crystalloids and high dose cate-
cholamines had to be applied. Due to respiratory failure,
the patient was intubated. On the next morning, a
marked pleural effusion with 1000 ml of exudative fluid
was drained. Despite all these measures, her respiratory
situation became worse with refractory hypoxaemia and
increasing ventilation pressures, compelling us to install
an interventional lung assist device. After this, her situa-
tion stabilized markedly. To this point, no other organ
failures had occurred.
Streptococcus pyogenes grew in all four blood cultures
drawn at admission and from the bronchoalveolar
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lavage. RT-PCR of the bronchoalveolar lavage for Influ-
enza B was positive with 3,568 copies/ml and suggested
a primary influenza infection with bacterial super infec-
tion (Table 1). Antibiotic treatment was changed to
high-dose penicillin (5 Mio U four times a day) and
oseltamivir 75 mg twice daily was added (on day 5 after
admission) for 5 days. On day seven, ventilator asso-
ciated pneumonia was suspected and bronchoalveolar
lavage repeated. No causative agent was identified, and
another Influenza RT-PCR was negative for Influenza B.
Fifteen days after admission, a sudden respiratory
deterioration occurred with pulmonary hemorrhage,
compounding mechanical ventilation markedly. A
bronchoscopy showed crustal lesions in the trachea but
no active bleeding. On suspicion of pneumothoraces,
thoracic drainages were inserted bilaterally. A malfunc-
tion of the interventional lung assist device made a
change of the device necessary. The invasive procedure
was poorly tolerated, and temporary mechanical resusci-
tation had to be performed. Thereafter, the patient
remained dependant on high dose catecholamines and
showed persistent signs of cerebral hypoxaemia. The
patient died 18 days after admission. Autopsy was
declined by the family for religious reasons.
Patient 3
A 61-year-old previously healthy woman was admitted
to hospital after returning from a one week of holiday
Table 1 Characteristics of three previously healthy patients with primary Influenza B infection, severe bacterial
pneumonia and septic shock
Characteristic Patient 1 Patient 2 Patient 3
Date of admission February 2008 March 2008 March 2008
Days of hospitalization 56 18 26
Age (years) 40 27 61
Co-morbidities None None Osteoporosis
Septic shock *
Tachycardia (beats/min) 160 120 110
Tachypnoea (rate/min) 40 45 30
Hypotension Yes Yes Yes
Fever (°C) 40 39 39
Leukocyte count (×10S9/l) 2.96 12.4 14.2
Microbiology
Initially isolated bacteria S. pyogenes† S. pyogenes† S. pneumoniae‡
Influenza B RT-PCR § Positive Positive Positive
Influenza A RT-PCR § Negative Negative Negative
Initial therapy Piperacillin/Tazobactam Amoxicillin/clavulanic acid plus Clarithromycin Ceftriaxon plus Clarithromycin
Final therapy Penicllin plus Penicillin plus Vancomycin plus
Oseltamivir Oseltamivir Oseltamivir
Laboratory findings ||
CRP (mg/l) 507 445 329
PCT (ng/ml) 203 113 3.71
Arterial blood gas ||
pH 7.19 7.28 7.45
paO2 (kPa) 8.7 9.72 6.59
paCO2 (kPa) 8.9 4.84 4.95
BE -4.6 -8.8 2.5
Lactate (mmol/l) 1.4 5.1 2.5
Death on day - 18 -
* Defined as patients showing all of following abnormal findings: tachycardia, tachypnoe, fever, leukocytosis or -penia and hypotension. Data printed are from
the time of admission.
† Results from bronchoalveolar lavage and blood cultures.
‡ Result from urine pneumococcal antigen test.
§ Real-time quantitative PCR from tracheal aspirate detecting Influenza A and B in separate reactions confirmed in at least two separate exams.
|| Values showing the greatest deviation from normal during the first two days after admission. All blood gas data were obtained while applying high flow
oxygen through a non re-breathing mask.
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in Morocco. She complained of headaches, a sore throat,
no appetite and general weakness since 9 days, and
mentioned having diarrhoea since 6 days. She was
started on amoxicillin 750 mg three times daily by a
family doctor without effect. The day she presented to
our emergency unit she was febrile with 38°C and
tachypnoeic. Auscultation detected rales bilaterally
and bilateral infiltrates were found on a chest x-ray.
Her laboratory findings showed a leukocyte count of
14 ×10-9/l and a CRP of 195 mg/l initially (Table 1). An
empiric antibiotic therapy with ceftriaxone 2 g/day and
clarythromycin 500 mg twice daily was initiated, and the
septic patient was transferred to the intensive care unit.
The pneumococcal antigen was positive in the urine
sampled on admission. Blood cultures remained nega-
tive, which may be explained by the antibiotic pretreat-
ment. A direct influenza antigen test was negative
initially.
Due to respiratory failure, the patient was intubated
on day 4 despite non-invasive ventilation. A sponta-
neous right-sided pneumothorax was treated with a
thoracic drainage. Over the next few hours, her respira-
tory situation deteriorated further showing a progressive
hypoxaemia and a reduced lung compliance requiring
an interventional lung assist device. With the suspicion
of penicillin-resistant pneumococci in this patient return-
ing from Morocco, the antibiotic therapy was changed
to vancomycin 1 g twice daily. A second urine test for
pneumococcal antigen was again positive. No other bac-
teria was detected in a bronchial alveolar lavage five
days after admission, but RT-PCR from a bronchial
alveolar lavage on day 5 revealed Influenza B with
12,231 copies/ml (Table 1). Oseltamivir 75 mg twice
daily was added (on day 9 after admission) for 5 days,
and the RT-PCR repeated thereafter remained positive
with 13,363 copies/ml for Influenza B. Seven days after
admission, the pulmonary situation had stabilized
enough that the interventional lung assist device could
be safely removed. One day later she was extubated.
The patient was transferred to a rehabilitation facility
26 days after admission.
This is the first report of Influenza B infections
accompanied by severe bacterial superinfection in three
healthy women.
Fatal co-infections of influenza virus with Streptococ-
cus pneumoniae have been described in mice since the
early eighties [6], and have been reported following in
clinical outbreaks [7]. In addition to S. pneumoniae, the
most common co-infecting bacteria are Staphylococcus
aureus, Haemophilus influenzae, Streptococcus pyogenes
and Mycoplasma pneumoniae. Pathophysiologically var-
ious data from mice models suggests that influenza
virus infection damages the epithelium of the bronchi
and lungs, allowing microaspirated bacterial pathogens
to establish infection [8]. On the other hand, influenza
alters the local immunity [9] and the inflammatory
response [10-12] facilitating the outgrowth of bacteria.
Underlying immunosuppression might lead to more
severe and prolonged disease [13]. Our patients pre-
sented with no evidence of underlying disease or other
known risk factors for dual infection such as age (< one
year, > 65 years), pregnancy or comorbidity [14].
From an epidemiological viewpoint, the circulating
strain is known to contribute to mortality with H3N2
subtype causing more influenza-associated deaths than
H1N1 or influenza B viruses [15]. Influenza B leads to
fewer co-infections [16] and milder disease compared to
Influenza A [8,17]. In Switzerland, the seasonal influenza
epidemics of 2007/2008 were characterized by an initial
increase in Influenza A H3N2 cases, whereas in the later
months, when our patients presented, infections with
Influenza B prevailed [17] (Figure 1). The predominant
circulating B strain in Switzerland was B/Jiangsu/10/03.
This strain was not matched by a corresponding strain
in the B component of the vaccine and was not present
in the previous year (Figure 2), therefore, it is possible
that there is no immunologic memory for this infection,
perhaps contributing to the severity of infection [18].
The first and second patient had young children suffer-
ing from influenza-like symptoms and most probably
transmitted the virus to their mother. In general, we do
not think that there is an association between sex and
disease severity. While pregnancy was associated with
poor outcome in the H1N1 pandemics, none of our
patients was pregnant.
Diagnosis in our cases was based on real-time quanti-
tative PCR, according to a previously published protocol
detecting Influenza A and B in separate reactions with a
limit of detection of 2.5 log10 copies/ml [19]. This
method is known to be very sensitive and specific com-
pared to antigen testing, which is a more rapid but less
sensitive test, and was negative in one of our three
patients. Severe cases of Influenza B have probably
always occurred. But as most routine laboratories did no
specific testing for Influenza B, this could not be docu-
mented until recently. Interestingly, a recent study on
the effect of oseltamivir in patients hospitalized with
Influenza infection included 215 patients with influenza
B, of which 13 died, confirming our data on serious
courses of Influenza B infections [20].
All three patients received oseltamivir, a highly selec-
tive neuraminidase-inhibitor. This agent is effective
against Influenza A and B. Although clinical data are
limited in Influenza B, some evidence exists that oselta-
mivir might have less effect on Influenza B, therefore,
higher dosing may be necessary [21]. Patient 1 received
an early empiric treatment with oseltamivir, as her his-
tory was indicative for primary influenza infection and
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bacterial superinfection. In the other two patients, anti-
viral treatment was started only later, on day 5 in the
second and at day 9 in the third patient. Given the fact
that antiviral treatment is efficacious especially in the
early course, empirical use of oseltamivir in severe pneu-
monia during an influenza season might be advisable,
even though PCR-testing is a highly sensitive and rea-
sonably rapid. With regard to oseltamivir’s properties
and the fact that septic patients are immunocompro-
mised per se, the early use of neuraminidase-inhibitors
seems warranted. In fact, our case series favours the
approach of empirical combined antiviral-antibiotic
treatment, a discussion that evolved during the H1N1
pandemics. However, there is no evidence that the use
of oseltamivir yields any benefit after 48 hours of
infection.
Supportive care measures for septic shock and respira-
tory failure were taken immediately. Minimal inhibitory
concentrations for penicillin were low in the two cases
with S. pyogenes indicating full susceptibility towards the
administered empirical betalactam antibiotic. To prevent
toxin production, clindamycin was added. S. pyogenes is
known to cause fulminant toxic shock syndromes, for
which both patients qualify, occurring also in young and
previously healthy persons [22]. In the third case, no
resistance testing was available due to diagnosis of S.
pneumoniae by means of a non-cultural assay only. A
penicillin-resistant strain might have been possible in
the patient returning from Morocco, where the local
epidemiology shows up to 40% penicillin-resistant pneu-
mococci [23] and, therefore, may have contributed to
delay in a correct antibiotic treatment.
The application of an interventional lung assist
enables a safe application of lung protective ventilation
[24] together with a therapy of respiratory acidosis in
patients where all other intensive care measures have
failed to provide adequate ventilation and decarboxyla-
tion. Although uncommonly used on our ward, the lung
assist device allowed us to combine very low tidal
volumes (3-6 ml/kg) and high PEEP levels with lower
plateau pressures and, thus, the avoided barotraumas
reported in these patients. Especially during acute lung
injury due to pneumonia, the application of low tidal
ventilation may prevent secondary injury from mechani-
cal ventilation to the uninfected parts of the lung.
Conclusions
Influenza B infection can pose a risk for severe second-
ary infection in previously healthy persons. As patients
admitted to hospital due to severe pneumonia are rarely
tested for Influenza B, the incidence of admission due to
this virus might be greatly underestimated, therefore, a
more aggressive search for influenza virus and empirical
treatment might be warranted. While the use of an
interventional lung assist device offers a potential treat-
ment strategy for refractory respiratory acidosis in addi-
tion to protective lung ventilation, the combined
empiric use of a neuraminidase-inhibitor and antibiotics
in septic patients with pulmonary manifestations during
an epidemic season should be considered.
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